Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease

Neuroscience Letters

Volumn 497, Issue 1, 2011, Pages 6-10

  Klinge, Petra M ^a   Harmening, Kathrin ^b   Miller, Miles C ^a   Heile, Anna ^b   Wallrapp, Christine ^c   Geigle, Peter ^c   Brinker, Thomas ^a,b  

^a BROWN UNIVERSITY   (United States)

^b INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^c CellMed AG   (Germany)

Author keywords

Alzheimer's disease; Cell encapsulation; Cell therapy; Glucagon like peptide 1; Mesenchymal stem cell

Indexed keywords

AMYLOID BETA PROTEIN; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; RECOMBINANT GLUCAGON;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTAL LOBE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALGINATES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOCOMPATIBLE MATERIALS; CAPSULES; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GLUCAGON-LIKE PEPTIDE 1; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, TRANSGENIC; TRANSFECTION;

EID: 79956037142     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.03.092     Document Type: Article

References (29)

1. Borlongan C.V. Cell therapy for stroke: remaining issues to address before embarking on clinical trials. Stroke 2009, 40:S146-S148.
2. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
3. Fang F., Lue L.F., Yan S., Xu H., Luddy J.S., Chen D., Walker D.G., Stern D.M., Schmidt A.M., Chen J.X., Yan S.S. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 2010, 24:1043-1055.
4. Fuller S., Steele M., Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease-do they neglect their neurosupportive roles?. Mutat. Res. 2010, 690:40-49.
5. Gordon M.N., Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.W., Connor K., Melachrino J., O'Callaghan J.P., Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp. Neurol. 2002, 173:183-195.
6. Heile A.M., Wallrapp C., Klinge P.M., Samii A., Kassem M., Silverberg G., Brinker T. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci. Lett. 2009, 463:176-181.
7. Hernandez R.M., Orive G., Murua A., Pedraz J.L. Microcapsules and microcarriers for in situ cell delivery. Adv. Drug Deliv. Rev. 2010, 62:711-730.
8. Iwai T., Ito S., Tanimitsu K., Udagawa S., Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci. Res. 2006, 55:352-360.
9. Lee H.J., Lee J.K., Lee H., Shin J.W., Carter J.E., Sakamoto T., Jin H.K., Bae J.S. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. Neurosci. Lett. 2010, 481:30-35.
10. Lee J.K., Jin H.K., Bae J.S. Bone marrow-derived mesenchymal stem cells attenuate amyloid beta-induced memory impairment and apoptosis by inhibiting neuronal cell death. Curr. Alzheimer Res. 2010, 7:540-548.
11. Lee J.K., Jin H.K., Bae J.S. Bone marrow-derived mesenchymal stem cells reduce brain amyloid-beta deposition and accelerate the activation of microglia in an acutely induced Alzheimer's disease mouse model. Neurosci. Lett. 2009, 450:136-141.
12. Lindvall O., Wahlberg L.U. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp. Neurol. 2008, 209:82-88.
13. Masliah E., Sisk A., Mallory M., Games D. Neurofibrillary pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. J. Neuropathol. Exp. Neurol. 2001, 60:357-368.
14. Matsuoka Y., Picciano M., Malester B., LaFrancois J., Zehr C., Daeschner J.M., Olschowka J.A., Fonseca M.I., O'Banion M.K., Tenner A.J., Lemere C.A., Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 2001, 158:1345-1354.
15. Perry T., Greig N.H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimers Dis. 2002, 4:487-496.
16. Perry T., Haughey N.J., Mattson M.P., Egan J.M., Greig N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther. 2002, 302:881-888.
17. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003, 72:603-612.
18. Prinz M., Mildner A. Microglia in the CNS: immigrants from another world. Glia 2011, 59:177-187.
19. Simonsen J.L., Rosada C., Serakinci N., Justesen J., Stenderup K., Rattan S.I., Jensen T.G., Kassem M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat. Biotechnol. 2002, 20:592-596.
20. Takeuchi A., Irizarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., Mann D.M., Hyman B.T., Iwatsubo T. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 2000, 157:331-339.
21. Ting K.K., Brew B., Guillemin G. The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox. Res. 2007, 12:247-262.
22. Tuppo E.E., Arias H.R. The role of inflammation in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2005, 37:289-305.
23. von Bernhardi R. Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox. Res. 2007, 12:215-232.
24. von Bernhardi R., Eugenin J. Microglial reactivity to beta-amyloid is modulated by astrocytes and proinflammatory factors. Brain Res. 2004, 1025:186-193.
25. Wang D.S., Dickson D.W., Malter J.S. Beta-amyloid degradation and Alzheimer's disease. J. Biomed. Biotechnol. 2006, 2006:58406.
26. Wang Y.J., Zhou H.D., Zhou X.F. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov. Today 2006, 11:931-938.
27. Wegiel J., Wang K.C., Tarnawski M., Lach B. Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol. 2000, 100:356-364.
28. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35:419-432.
29. Zilka N., Ferencik M., Hulin I. Neuroinflammation in Alzheimer's disease: protector or promoter?. Bratisl Lek Listy 2006, 107:374-383.